Partnership between Avulux and Eyenavision offers elevated
patient care and accelerated practice growth opportunities for
eyecare providers
PITTSBURGH & MIAMI, Aug. 19,
2024 /PRNewswire/ - Avulux and Eyenavision today
launched Chemistrie Avulux, an innovative new on-demand eyeglass
clip option for people living with migraine and light sensitivity.
The product combines patented, clinically proven Avulux Migraine
& Light Sensitivity Lenses with the Chemistrie Lens Layering
System, the patented clip-on system that attaches through the use
of magnets embedded in the lenses.
"We are excited to partner with Avulux to introduce Chemistrie
Avulux," said Joe Zewe, Chief
Executive Officer of Eyenavision. "Through the combination of
our unique products, eyecare providers can now offer a seamless,
on-demand solution for patients who suffer from migraine and light
sensitivity. This collaboration underscores Eyenavision's
commitment to expanding patient access to lifestyle-enhancing
products through our versatile and customizable Chemistrie
system."
In addition to being a convenient option for people experiencing
migraine and light sensitivity, the new Chemistrie Avulux lens also
offers all the light filtration properties that Avulux is known
for: blocking up to 97 percent of harmful blue, amber and red
lightwaves linked to triggering or worsening migraine attacks,
while letting in soothing green light.
Available now through Eyenavision's Chemistrie Certified Lab
partners, Chemistrie Avulux will help more eyecare providers (ECPs)
expand their scope of practice and offer premium care to patients
experiencing migraine.
Migraine, a complex genetic neurological disorder that often
includes symptoms such as severe headaches, nausea, sensitivity to
light, and visual disturbances, affects nearly 48 million Americans
– or as many as one in every five patients in an ECP's practice.
For many of these patients, migraine is triggered or worsened by
light. "ECPs can play a key role in caring for patients with
migraine and light sensitivity," said Dr. Charles Posternack, Chief Executive Officer of
Avulux. "We are thrilled to partner with Eyenavision to help ECPs
expand their scope of practice and support even more patients with
the innovative new Chemistrie Avulux clips."
About Avulux Migraine & Light
Sensitivity Lenses
Avulux is the world's only clinically proven lens that blocks
the harmful light wavelengths linked to migraine attacks. Up to 90
percent of people with migraine experience light sensitivity during
a migraine attack. The Avulux Migraine & Light Sensitivity Lens
is patented technology, blocking up to 97 percent of harmful blue,
amber and red light while letting in over 70 percent of soothing
green light.
The Avulux Migraine & Light Sensitivity Lens is available
through eye care providers and optical retailers in the U.S.,
Canada, Australia, New
Zealand and the U.K. Learn more at ecp.avulux.com.
About Eyenavision, Inc.
Based in Pittsburgh,
Eyenavision develops innovative products and services to simplify
the lives of independent eyecare providers and their patients.
Chemistrie, Eyenavision's flagship product, is the best-selling
custom eyeglass clip solution fabricated by more than 100 labs and
sold through more than 5,000 independent optical retailers across
the U.S. and around the world.
Utilizing the patented Chemistrie magnetic lens layering system,
eyecare providers can support their patients through a simple,
versatile solution. Patients can enhance the comfort, quality and
performance of their primary eyewear with the flexibility of
multiple click-on lenses with numerous style and functional
features. For more information, please
visit eyenavision.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avulux-and-eyenavision-introduce-chemistrie-avulux-clips-for-people-living-with-migraine-and-light-sensitivity-302225731.html
SOURCE Avulux